Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RQ3033 Omicron XBB.1.5 mRNA booster immunobridging trial in adults
ChiCTR2300077397Phase 3Recruiting
- Sponsor
- Yunnan Provincial Center for Disease Control and Prevention
- Start
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of RQ3033 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Yunnan Provincial Center for Disease Control and Prevention. Primary endpoints: Live virus neutralizing antibody against current major SARS-CoV-2 VOC and Incidence rate of adverse reaction/event. Started Nov 2023; status: recruiting.
02
Drugs
RQ3033
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300077397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077397.